AZ HB2101

Establishes the vaccine financing and availability study committee consisting of 14 voting members representing state legislators, health insurers, health care providers, local health departments, nonprofit organizations, vaccine manufacturers, pharmacists, and employers, plus 3 non-voting advisory members from state agencies.

Requires the committee to develop recommendations on the existing system of financing and availability of childhood and adolescent vaccines and their impacts on the health care system, taxpayers, and communities.

Directs the committee to examine costs and adequacy of reimbursement levels for vaccines administered by private and public providers across all Arizona counties.

Authorizes the committee to request information from state agencies and other entities, hold hearings, and maintain confidentiality of business information disclosed during its work.

Requires the committee to submit a written report of findings and recommendations to the governor, legislature, and secretary of state by December 15, 2014, with the committee itself repealing on December 31, 2015.